A pharmaceutical plant worth 2.5 billion rubles will be built in the Moscow region

JSC Pharmaceutical Enterprise Obolenskoe (OBL Pharm) will build a plant for the production of solid dosage forms worth 2.5 billion rubles in the Serpukhov district of the Moscow Region. This was reported by the press service of the Ministry of Construction of the Moscow Region.

"The company plans to invest 2.5 billion rubles in the construction of new production facilities, which will increase production volumes for both the current product range and drugs planned for release. The launch of the licensed enterprise is scheduled for October 2018," said the head of the department, Sergey Pakhomov.

It is assumed that the enterprise will be built on the territory of the Obolensk settlement in the Serpukhov district.

"Production facilities with a built-up area of over 13,000 square meters, an administrative-laboratory building, and auxiliary buildings with an area of 6,000 square meters will be constructed on a territory of 6 hectares," notes the press service of the Ministry of Construction of the Moscow Region.

According to Pakhomov, the plant will provide the district with about 300 jobs.

In September 2013, the Cypriot company Alvansa Limited, whose main shareholders are Gazprombank and the investment fund UFG Private Equity, acquired an 80.55% stake in FP Obolenskoe.

FP Obolenskoe was founded in 1994 on the basis of the State Research Center for Applied Microbiology. The company is engaged in the production of medicines and medical devices, manufacturing over 100 drug names. According to SPARK data, the company's revenue for 2015 amounted to 3.1 billion rubles, with a net profit of 551.6 million rubles.